Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease

Jane L Benjamin, Charlotte R H Hedin, Andreas Koutsoumpas, Siew C Ng, Neil E McCarthy, Ailsa L Hart, Michael A Kamm, Jeremy D Sanderson, Stella C Knight, Alastair Forbes, Andrew J Stagg, Kevin Whelan, James O Lindsay

Research output: Contribution to journalArticlepeer-review

227 Citations (Scopus)

Abstract

The commensal intestinal microbiota drive the inflammation associated with Crohn's disease. However, bacteria such as bifidobacteria and Faecalibacterium prausnitzii appear to be immunoregulatory. In healthy subjects the intestinal microbiota are influenced by prebiotic carbohydrates such as fructo-oligosaccharides (FOS). Preliminary data suggest that FOS increase faecal bifidobacteria, induce immunoregulatory dendritic cell (DC) responses and reduce disease activity in patients with Crohn's disease.
Original languageEnglish
Pages (from-to)923-9
Number of pages7
JournalGut
Volume60
Issue number7
DOIs
Publication statusPublished - Jul 2011

Keywords

  • Adult
  • Bifidobacterium
  • Crohn Disease
  • Dendritic Cells
  • Double-Blind Method
  • Feces
  • Female
  • Humans
  • Immunity, Mucosal
  • Intestinal Mucosa
  • Male
  • Medication Adherence
  • Middle Aged
  • Oligosaccharides
  • Prebiotics
  • Rectum
  • Treatment Outcome

Cite this